Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

Open access
Furumoto, Yasuko, Smith, Carolyne K., Blanco, Luz, Zhao, Wenpu, Brooks, Stephen R., Thacker, Seth G., Zarzour, Abdalrahman, Sciumè, Giuseppe, Tsai, Wanxia L., Trier, Anna M., Nunez, Leti, Mast, Laurel, Hoffmann, Victoria, Remaley, Alan T., O'Shea, John J., Kaplan, Mariana J., Gadina, Massimo · 2017 · Arthritis & Rheumatology

Abstract

Objective: Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. No drug to date targets both systemic inflammatory disease and the cardiovascular complications of SLE. Tofacitinib is a JAK inhibitor that blocks signaling downstream of multiple cytokines implicated in lupus pathogenesis. While clinical trials have shown that tofacitinib exhibits significant clinical efficacy in various autoimmune diseases, its role in SLE and the associated vascular pathology remains to be characterized. Methods: MRL/lpr lupus‐prone mice were administered tofacitinib or vehicle by gavage for 6 weeks (therapeutic arm) or 8 weeks (preventive arm). Nephritis, skin inflammation, serum levels of autoantibodies and cytokines, mononuclear cell phenotype and gene expression, neutrophil extracellular traps (NETs) release, endothelium‐dependent vasorelaxation, and endothelial differentiation were compared in treated and untreated mice. Results: Treatment with tofacitinib led to significant improvement in measures of disease activity, including nephritis, skin inflammation, and autoantibody production. In addition, tofacitinib treatment reduced serum levels of proinflammatory cytokines and interferon responses in splenocytes and kidney tissue. Tofacitinib also modulated the formation of NETs and significantly increased endothelium‐dependent vasorelaxation and endothelial differentiation. The drug was effective in both preventive and therapeutic strategies. Conclusion: Tofacitinib modulates the innate and adaptive immune responses, ameliorates murine lupus, and improves vascular function. These results indicate that JAK inhibitors have the potential to be beneficial in SLE and its associated vascular damage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.39818

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 217

Metadata

Authors
Furumoto, Y., Smith, C. K., Blanco, L., Zhao, W., Brooks, S. R., Thacker, S. G., Zarzour, A., Sciumè, G., Tsai, W. L., Trier, A. M., Nunez, L., Mast, L., Hoffmann, V., Remaley, A. T., O'Shea, J. J., Kaplan, M. J., & Gadina, M.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2016-12-28
Volume
69
Issue
1
Pages
148-160
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W2504534335
Cited by
217
References
2
FWCI
21.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.